Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

NCT04141306 | Unknown

• 1 other identifier: 69HCL19_1919
• Study Type: observational
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Bone radioiodine (RAI) uptake without structural abnormality in thyroid cancer (TC) patients may be related to false positive or to microscopic foci of metastatic tissue. In such cases, outcome is reported to be excellent. Indeed, Robenshtok et al. reported a serie of patients with RAI-avid bone metastases of TC without structural abnormality on imaging studies who have more favorable long-term prognosis than those harbouring structurally visible bone metastases and do not undergo skeletal-related complications. The investigators report the case of Mrs D., who had been operated for a pathologic tumor stage 3: pT3(m) poorly differentiated TC at the age of 43. The first post-therapeutic whole body scan revealed 3 foci of bone uptake (right clavicle, L2, L3). The elevated level of thyroglobulin (157ng/mL) favoured the hypothesis of bone metastases despite the absence of any structural lesion on CT and MRI. She received 7 courses of radioiodine therapy. The right clavicle RAI uptake persisted, and subsequent CT disclosed an osteolytic lesion which was treated by radiofrequency and external beam radiation. Twenty-five years after the diagnosis, she has a persistent morphological disease with a 30x8mm progressive lesion on the right clavicle, for which surgery is planned. The aim of the present study is to describe the natural history and evolution of radioiodine avid bone metastases from thyroid cancer without structural abnormalities and to identify prognosis factors.

Conditions

Bone Metastases; Thyroid Cancer

Keywords

Radioiodine Bone Metastases; Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

• Rate of complete remission of thyroid cancer

  * Disappearance of pathologic radio iodine uptake, including bone uptake, on post-therapy scintigraphy * No structural evidence of disease on high-resolution imaging * Suppressed serum Tg \< 0.6 ng/mL, no detectable TgAb (thyroglobulin antibody)

  1 month

Interventions

Administrative data OTHER

Evaluation of month and year of birth, sex, referent doctor and surgeon

Clinical data OTHER

Evaluation of diagnostic circumstances, vital status at last follow up

Histological data OTHER

Evaluation of Pathology report of thyroid surgery

Imaging data OTHER

Evaluation of scintigraphy, MRI, scan

Biological data OTHER

Evaluation of thyroglobulin, antithyroglobulin antibodies

Further treatment OTHER

Evaluation of surgery, radiotherapy, targeted therapy

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who received total thyroidectomy in a context of differentiated thyroid cancer showing at post-therapy scintigraphy at least one radioiodine bone uptake without structural correlation on high-resolution imaging

You may qualify if:

• Differentiated thyroid cancer
• Ablation therapy with post dose scintigraphy
• At least one radioiodine bone uptake without structural correlation on high-resolution imaging

You may not qualify if:

• A single radio iodine bone uptake with structural correlation on imaging
• Diagnosis of bone metastasis after a skeletal related event including spinal cord compression, pathological fracture, need for external beam radiation, surgery to bone, or development of hypercalcemia of malignancy
• Follow up less than 6 months
• Missing data in medical record

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

MeSH Terms

Conditions

Thyroid Neoplasms

Interventions

Routinely Collected Health Data

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Intervention Hierarchy (Ancestors)

Health Care Surveys; Health Services Research; Health Planning; Health Care Economics and Organizations; Health Care Quality, Access, and Evaluation

Central Study Contacts

Claire BOURNAUD, MD

CONTACT

4 72 35 69 99; claire.bournaud-salinas@chu-lyon.fr

Claire MARX

CONTACT

claire.marx@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2019
• First Posted: October 28, 2019
• Study Start: November 1, 2019
• Primary Completion: December 1, 2019
• Study Completion: December 1, 2019
• Last Updated: October 28, 2019

Record last verified: 2019-10